Data gaps limit the translational potential of preclinical research

Area of Science:

• Pharmacokinetics and Drug Development
• Preclinical Research Methodology
• Neuroscience Drug Discovery

Background:

• Mouse pharmacokinetic reference data is critically absent, impeding the translation of preclinical findings to clinical applications.
• A literature review revealed a consistent lack of justification for dosing strategies in preclinical research.
• Neuroscience studies are particularly affected, as inadequate brain penetration of drug candidates can restrict target engagement and efficacy.

Purpose of the Study:

• To highlight the critical need for robust mouse pharmacokinetic data.
• To identify and analyze the shortcomings in dosing paradigm selection within preclinical literature.
• To propose actionable solutions for improving the design of preclinical studies, particularly in neuroscience.

Main Methods:

• Systematic analysis of recent scientific literature focusing on preclinical study designs.
• Evaluation of the reported rationale for dosing paradigms in selected studies.
• Assessment of factors contributing to limited target-organ exposure, such as brain penetration.

Main Results:

• A significant deficit in mouse pharmacokinetic reference data was confirmed.
• Preclinical studies frequently lack a clear rationale for chosen dosing regimens.
• Poor drug brain penetration is a common limitation in neuroscience preclinical research, affecting exposure.

Conclusions:

• Establishing standardized mouse pharmacokinetic data is essential for reliable preclinical research.
• Improved transparency and justification for dosing strategies are required in study publications.
• Implementing refined study designs can enhance the predictive value of preclinical neuroscience research for clinical outcomes.